Vioxx Lawyers Web Log | |
Ask a Vioxx Lawyer, Vioxx Lawyer: Case Form
|
Ask a Vioxx Lawyer, "Do I have a Vioxx Case?" : Vioxx Blog : February 2005 : 2005-02-04
Merck & Co. Inc.'s painkiller Arcoxia offers a "marginal" advantage in gastrointestinal safety but appears "worse than" other pain drugs as well as a placebo in terms of deaths and serious cardiovascular problems, U.S. regulatory staff said in documents released on Friday.
February 4, 2005 18:45
WASHINGTON, Feb 4 (Reuters) - U.S. regulatory staff said a Novartis AG
Prexige, which is not yet approved in the United States, showed greater cardiovascular risks compared to naproxen but similar risks compared to ibuprofen, the reviewers said. The trial also showed Prexige had offered an "advantage" over other pain drugs that can cause stomach problems.
|
Home | Site Map | Disclaimer